SEARCH

SEARCH BY CITATION

References

  • 1
    Locke GR, Talley NH, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted county. Gastroenterology 1997;112:144856.
  • 2
    Dickman R, Mattek N, Holub J, et al. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol 2007;102:11739.
    Direct Link:
  • 3
    Sandler RS, Everhard JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:150011.
  • 4
    Katelaris PH. An evaluation of current GERD therapy: a summary and comparison of effectiveness, adverse effects and costs of drugs, surgery and endoscopic therapy. Best Pract Res Clin Gastroenterol 2004;18(Suppl.):S3945.
  • 5
    Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005;23:1325.
  • 6
    Theida P, Beard S, Richter A, et al. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003;54: 50816.
  • 7
    Cleemput I, Kesteloot K, Degeest S. A review of the literature on the economics of noncompliance: room for methodological improvement. Health Policy 2002;59:6594.
  • 8
    Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:60115.
  • 9
    Hall J, Dodd S, Durkin M, et al. Impacts of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag Care 2002;1(Suppl.7):S1418.
  • 10
    Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:44957.
  • 11
    Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:67074.
  • 12
    Ward A, Ishak K, Proskorovsky I, et al. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006;28:191221.
  • 13
    Devault KR. Extraesophageal symptoms of GERD. Cleve Clin J Med 2003;70(Suppl.5):S2032.
  • 14
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:61319.
  • 15
    Pfizer Inc. Celebrex Product Information, February 2005 [online]. Available from: http://www.pfizer.com/pfizer/download/uspi_celebrex.pdf[Accessed June 6, 2007.
  • 16
    Roche Pharmaceutical. Naproxen Product Information, January 2006 [online]. Available from: http://www.rocheusa.com/products/naprosyn/pi.pdf[Accessed June 6, 2007.
  • 17
    Hawkey CF. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? Aliment Pharmacol Ther 2004;20(Suppl. 2):S5964.